Perdagangan Vir Biotechnology VIR

VirBiotechnology diagram langsung

Dasar-dasar Instrumen

Weekly Search
Weekly
Daily
Tanggal Tutup Ubah Ubah (%) Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tampilkan lebih banyak
Ava Grace 2025 Jul 16, 13:20

Israel Escalates Syria Strikes: Damascus Targeted Amid Sectarian Violence Surge

Noah Lee 2025 Jul 16, 11:20

Analyzing Trump's Social Media Impact on Financial Markets

Noah Lee 2025 Jul 16, 09:21

Trump-Era Advisor Leading Contender for Next Fed Chair

Liam James 2025 Jul 16, 08:20

NVIDIA CEO Huang Praises Chinese AI, Reaffirms Commitment to China Market

Emma Rose 2025 Jul 16, 08:20

Gold as a Safe Haven: Investment Strategies Amid Trade Tensions - Morgan Stanley, Goldman Sachs & UBS Analysis

Noah Lee 2025 Jul 16, 08:00

US Expands Deportations, Sends Violent Criminals to Eswatini: A Controversial Policy Examined

Ava Grace 2025 Jul 16, 07:20

Morgan Stanley: Global Oil Inventories Swell, But Prices Temporarily Supported

Sophia Claire 2025 Jul 16, 05:20

Trump Threatens to Fire Powell Over Fed's Costly Renovation: Is Central Bank Independence at Risk?

Info

Spread

0.05

Spread (%)

0.9276 %

Leverage

1:10

Bunga Overnight Beli

-0.0597 %

Bunga Overnight Jual

-0.0292 %

Mata Uang

USD

Jam Trading

Pasar tutup

Kamis

13:31 - 19:59

Senin

13:31-19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Jumat

13:31-19:59

Analisis dan Statistik

Buka

---

Sebelumnya Tutup

---

52 Minggu Tigg/Rdh

--- – ---

Kapitalisasi Pasar

732661440

Saham yang Beredar

138238000

Tanggal Penghasilan (Berikutnya)

0000-00-00

Hasil Div

Tanggal Non-Dividen

Proyeksi tingkat dividen tahunan

0

Proyeksi hasil dividen tahunan

0

EPS

-4.23

Pelajari lebih lanjut tentang instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

latest_education_articles

Tampilkan lebih banyak
Trustpilot